Arvinas, Inc.
NASDAQ:ARVNBiotechnology
Healthcare
$6.77 -1.30%
-$0.10 today
- Market cap
- $443.01M
- Beta
- 1.75
- P/E (TTM)
- -2.2
- EPS (TTM)
- -$3.46
52W Low $6.06High $14.51
Volume 1.09M
Average 0.89M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$273.80M
FY 2025 · Annual
Investing Cash Flow
$407.60M
FY 2025 · Annual
+1074.6% YoYFinancing Cash Flow
-$91.40M
FY 2025 · Annual
Cash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (191M) | (282.5M) | (367.3M) | (198.9M) | (80.8M) |
| Depreciation & Amortization | 6M | 8.2M | 6.7M | 6.6M | 5.2M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 57.1M | 75.5M | 71.6M | 88.2M | 44M |
| Change in Working Capital | 678.3M | (82.6M) | (44.4M) | (140.6M) | (233.7M) |
| Accounts Receivables | (30.2M) | 14M | 800K | (5.7M) | 7.3M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 27.9M | 20.2M | 17.3M | (21.2M) | (1.7M) |
| Other Working Capital | 680.6M | (116.8M) | (62.5M) | (113.7M) | (239.3M) |
| Other Non-Cash Items | 9M | 7.9M | (14.4M) | (14.6M) | (8.5M) |
| Operating Cash Flow | 559.4M | (273.5M) | (347.8M) | (259.3M) | (273.8M) |
| Capital Expenditures | (4.7M) | (6.8M) | (2.9M) | (1.8M) | (1.9M) |
| Acquisitions (Net) | 0 | 400K | 0 | 100K | 0 |
| Purchases of Investments | (1.74B) | (886.4M) | (956.3M) | (652.1M) | (354.2M) |
| Sales of Investments | 435.7M | 1.14B | 1.16B | 688.5M | 763.7M |
| Other Investing Activities | 0 | (400K) | 0 | 0 | 0 |
| Investing Cash Flow | (1.31B) | 242.8M | 203.5M | 34.7M | 407.6M |
| Debt Repayment | 0 | 0 | 0 | (400K) | (200K) |
| Common Stock Issued | 264.6M | 4.7M | 387.2M | 8.3M | 700K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | (91.9M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 14M | 0 | 0 | 0 | 0 |
| Financing Cash Flow | 278.6M | 4.7M | 374.7M | 7.9M | (91.4M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (475.6M) | (26M) | 230.4M | (216.7M) | 42.4M |
| Free Cash Flow | 554.7M | (280.3M) | (350.7M) | (261.1M) | (275.7M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$80.8M
+ D&A$5.2M
+ Stock-Based Comp$44.0M
+ Deferred Tax$0
- Working Capital-$233.7M
- Other Non-Cash-$8.5M
= Operating Cash Flow-$273.8M
- Capex-$1.9M
= Free Cash Flow-$275.7M
Analysis
FY2025 free cash flow is -$275.7M. FCF conversion is 341.2% of net income. Operating cash flow was -$273.8M, with capex of -$1.9M. The largest bridge item is Working Capital at -$233.7M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 4 | Statement of changes in beneficial ownership | Nov 9, 2026 | |
| 10-Q | Quarterly report | Nov 3, 2026 | |
| S-3 | S-3 filing | Nov 3, 2026 | |
| 8-K | Current report | Nov 3, 2026 | |
| S-8 | S-8 filing | Sep 28, 2026 |
Does ARVN generate free cash flow?
Arvinas, Inc. (ARVN) generated -$275.70M of free cash flow in fiscal 2025.
How much operating cash flow does ARVN produce?
Operating cash flow was -$273.80M, before capital expenditures of $1.90M.
Continue the stock analysis
Jump to another research area for this company.